Skip to content

A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions

A Randomized Controlled Trial of Three Prophylactic Antibiotic Regimens for First Trimester Surgical Abortion

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02756403
Enrollment
181
Registered
2016-04-29
Start date
2016-03-31
Completion date
2017-07-31
Last updated
2022-02-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

First Trimester Abortion

Brief summary

This study, a double blinded randomized controlled trial, is being done to compare side effects of commonly used antibiotic regimens prior to same day abortion procedures. In total, 180 pregnant women in their first trimester of pregnancy (5 0/6-13 6/7 weeks gestation) will be randomized to receive one of the three commonly used antibiotics (azithromycin, doxycycline, metronidazole) for same day abortion procedures or placebo prior to their abortion procedure. Approximately, 30-60 mins after study drug administration, the procedure will be performed. A sub-study will be completed on 40 women who consent to endometrial sampling and to have their blood drawn.

Detailed description

Main Study: Women will be randomized to receive single oral doses of azithromycin 500 mg, doxycycline 200 mg, metronidazole 500 mg, or placebo. Computer-generated randomization will be used to assign participants to one of the four treatment arms. Women receiving placebo will receive antibiotic prophylaxis after completion of the study. Both the participants and the investigators will be blinded as to the treatment group. This will be accomplished by placing the study medication inside opaque gelatin capsules. We will randomize participants by assigning them to the next of the sequentially numbered sealed opaque study packets, containing the gelatin capsules with study medication inside. A second envelope will be opened after completion of all study procedure and will only say if the participant received placebo, so that additional antibiotics can be given. Participants will swallow the appropriate medication approximately 30-60 minutes prior to the surgical abortion (15-90 minutes range is acceptable). Study population will be all eligible patients undergoing surgical abortion in the first trimester at Washington Hospital Center and Planned Parenthood Metropolitan Washington. We will assess pain and side effects via written questionnaire at three different time points throughout the day, once at time of consent, before and after the procedure. Patients will be contacted within 1-2 weeks for follow-up and again pain and side effects will be assessed, as well. Sub-study: Forty (n=40) women will be recruited to undergo immediate post-procedure endometrial sampling. Sub-study patients will have a blood sample collected via venipuncture before leaving the procedure room, as well. No testing will be performed for participants receiving placebo. The primary objective is to determine if the side effects associated with individual medications are more similar to placebo than the others. The sub-study aims to explore our ability to identify bacteria within the uterine cavity. The objective is to assess the feasibility of identifying bacteria within the uterus after abortion.

Interventions

DRUGAzithromycin

500 mg

DRUGDoxycycline

200 mg

DRUGMetronidazole

500 mg

DRUGPlacebo

Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.

Sponsors

Society of Family Planning
CollaboratorOTHER
Medstar Health Research Institute
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Women in good general health. * English speaking. * Age 18 or over. * Seeking non-urgent surgical termination of pregnancy. * Gestational age of 5 0/7 to 13 6/7 weeks, confirmed by sonogram.

Exclusion criteria

* Less than 18 years of age. * Early pregnancy failure or fetal demise. * Poor general health that would prevent one from tolerating the medication or surgical procedure. * Intolerance, allergy, or contraindication to any of the study medications. * Inability to tolerate oral intake due to current nausea or vomiting. * Diagnosis of hyperemesis gravidarum with current pregnancy. * Need of an urgent surgical abortion. * Gestational age outside of 5-13 6/7 weeks by sonogram.

Design outcomes

Primary

MeasureTime frameDescription
Emesis Severity1 DayEmesis severity assessment collected at different time points (None, Mild, Moderate, Severe)
Nausea Scale1 DayNausea symptom was collected at different time points via surveys (None, Mild, Moderate, Severe)

Secondary

MeasureTime frameDescription
Pain ScaleDay 1Pain symptoms will be collected at different time points via surveys (None, Mild, Moderate, Severe)
Serum Antibiotic Levels3 hoursSerum antibiotic levels drawn at time of endometrial sampling in subset of patients
Endometrial Growth3 DaysEndometrial Growth on non-selective, Staph Selective, Strep Selective, and Gram negative selective Agar

Countries

United States

Participant flow

Participants by arm

ArmCount
Azithromycin
500 mg of Azithromycin Azithromycin: 500 mg
46
Doxycycline
200 mg of Doxycycline Doxycycline: 200 mg
42
Metronidazole
500 mg of Metronidazole Metronidazole: 500 mg
41
Placebo
Inactive Ingredient Placebo: Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
45
Total174

Withdrawals & dropouts

PeriodReasonFG000FG001FG002FG003
Overall StudyChanged Mind About Procedure0010
Overall StudyDid not complete Procedure0100
Overall StudyProtocol Violation0101
Overall StudyUnable to swallow medication0111

Baseline characteristics

CharacteristicTotalPlaceboMetronidazoleDoxycyclineAzithromycin
Age, Continuous26.6 years
STANDARD_DEVIATION 5.9
28.6 years
STANDARD_DEVIATION 6.1
26.5 years
STANDARD_DEVIATION 5.5
26.2 years
STANDARD_DEVIATION 6.4
25.1 years
STANDARD_DEVIATION 5
BMI28.3 kg/m^2
STANDARD_DEVIATION 7.3
29.0 kg/m^2
STANDARD_DEVIATION 7
29.5 kg/m^2
STANDARD_DEVIATION 8.5
27.0 kg/m^2
STANDARD_DEVIATION 7.3
27.8 kg/m^2
STANDARD_DEVIATION 6.2
Education
College Grad
28 Participants10 Participants4 Participants5 Participants9 Participants
Education
Graduate School
8 Participants2 Participants1 Participants3 Participants2 Participants
Education
HS Grad or Equivalent
62 Participants16 Participants13 Participants16 Participants17 Participants
Education
Less than High School
7 Participants0 Participants3 Participants0 Participants4 Participants
Education
Some College
69 Participants17 Participants20 Participants18 Participants14 Participants
Gestational age64.3 days
STANDARD_DEVIATION 15.7
67.5 days
STANDARD_DEVIATION 15.8
65 days
STANDARD_DEVIATION 12.2
63.9 days
STANDARD_DEVIATION 17.1
60.9 days
STANDARD_DEVIATION 16.8
Marital Status
Cohabitating
14 Participants4 Participants3 Participants1 Participants6 Participants
Marital Status
Divorced
5 Participants3 Participants1 Participants1 Participants0 Participants
Marital Status
Married
21 Participants5 Participants3 Participants9 Participants4 Participants
Marital Status
Separated
2 Participants2 Participants0 Participants0 Participants0 Participants
Marital Status
Single
132 Participants31 Participants34 Participants31 Participants36 Participants
Parous
Nulliparous
65 Participants17 Participants10 Participants17 Participants21 Participants
Parous
Parous
109 Participants28 Participants31 Participants25 Participants25 Participants
Prior Abortion
No
72 Participants11 Participants15 Participants21 Participants25 Participants
Prior Abortion
Yes
102 Participants34 Participants26 Participants21 Participants21 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
5 Participants2 Participants1 Participants0 Participants2 Participants
Race (NIH/OMB)
Black or African American
121 Participants34 Participants27 Participants31 Participants29 Participants
Race (NIH/OMB)
More than one race
20 Participants5 Participants4 Participants4 Participants7 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants0 Participants0 Participants0 Participants0 Participants
Race (NIH/OMB)
Unknown or Not Reported
4 Participants0 Participants2 Participants1 Participants1 Participants
Race (NIH/OMB)
White
24 Participants4 Participants7 Participants6 Participants7 Participants
Sex: Female, Male
Female
174 Participants45 Participants41 Participants42 Participants46 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants0 Participants0 Participants
Work Status
Full Time Student
17 participants4 participants4 participants5 participants4 participants
Work Status
Full Time Work
78 participants23 participants16 participants19 participants20 participants
Work Status
Homemaker
3 participants1 participants1 participants1 participants0 participants
Work Status
Other
1 participants1 participants0 participants0 participants0 participants
Work Status
Part Time Work
33 participants10 participants9 participants6 participants8 participants
Work Status
Unemployed
44 participants6 participants11 participants13 participants14 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
deaths
Total, all-cause mortality
0 / 410 / 460 / 420 / 45
other
Total, other adverse events
0 / 410 / 460 / 420 / 45
serious
Total, serious adverse events
1 / 410 / 460 / 420 / 45

Outcome results

Primary

Emesis Severity

Emesis severity assessment collected at different time points (None, Mild, Moderate, Severe)

Time frame: 1 Day

Population: 4 Subjects failed to complete the entire post-procedure survey: 1 Azithromycin group, 2 in Metronidazole group, 1 in Placebo group

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
AzithromycinEmesis SeverityBefore ProcedureMild1 Participants
AzithromycinEmesis SeverityBaselineModerate6 Participants
AzithromycinEmesis SeverityBaselineSevere8 Participants
AzithromycinEmesis SeverityBefore ProcedureNone43 Participants
AzithromycinEmesis SeverityAfter ProcedureMild2 Participants
AzithromycinEmesis SeverityBaselineNone20 Participants
AzithromycinEmesis SeverityAfter ProcedureSevere0 Participants
AzithromycinEmesis SeverityAfter ProcedureNone42 Participants
AzithromycinEmesis SeverityBefore ProcedureSevere0 Participants
AzithromycinEmesis SeverityBaselineMild12 Participants
AzithromycinEmesis SeverityAfter ProcedureModerate1 Participants
AzithromycinEmesis SeverityBefore ProcedureModerate2 Participants
DoxycyclineEmesis SeverityBaselineModerate6 Participants
DoxycyclineEmesis SeverityBaselineNone24 Participants
DoxycyclineEmesis SeverityBaselineMild8 Participants
DoxycyclineEmesis SeverityBaselineSevere4 Participants
DoxycyclineEmesis SeverityBefore ProcedureNone42 Participants
DoxycyclineEmesis SeverityBefore ProcedureMild0 Participants
DoxycyclineEmesis SeverityBefore ProcedureModerate0 Participants
DoxycyclineEmesis SeverityBefore ProcedureSevere0 Participants
DoxycyclineEmesis SeverityAfter ProcedureNone35 Participants
DoxycyclineEmesis SeverityAfter ProcedureMild1 Participants
DoxycyclineEmesis SeverityAfter ProcedureModerate5 Participants
DoxycyclineEmesis SeverityAfter ProcedureSevere1 Participants
MetronidazoleEmesis SeverityBaselineMild16 Participants
MetronidazoleEmesis SeverityAfter ProcedureModerate0 Participants
MetronidazoleEmesis SeverityBefore ProcedureModerate0 Participants
MetronidazoleEmesis SeverityBefore ProcedureSevere0 Participants
MetronidazoleEmesis SeverityBaselineNone13 Participants
MetronidazoleEmesis SeverityBaselineModerate11 Participants
MetronidazoleEmesis SeverityAfter ProcedureNone39 Participants
MetronidazoleEmesis SeverityBefore ProcedureMild0 Participants
MetronidazoleEmesis SeverityAfter ProcedureMild0 Participants
MetronidazoleEmesis SeverityBaselineSevere1 Participants
MetronidazoleEmesis SeverityBefore ProcedureNone41 Participants
MetronidazoleEmesis SeverityAfter ProcedureSevere0 Participants
PlaceboEmesis SeverityBefore ProcedureMild1 Participants
PlaceboEmesis SeverityAfter ProcedureSevere0 Participants
PlaceboEmesis SeverityBefore ProcedureNone44 Participants
PlaceboEmesis SeverityBefore ProcedureModerate0 Participants
PlaceboEmesis SeverityBaselineNone17 Participants
PlaceboEmesis SeverityAfter ProcedureModerate0 Participants
PlaceboEmesis SeverityAfter ProcedureMild0 Participants
PlaceboEmesis SeverityBefore ProcedureSevere0 Participants
PlaceboEmesis SeverityBaselineSevere5 Participants
PlaceboEmesis SeverityBaselineMild15 Participants
PlaceboEmesis SeverityBaselineModerate8 Participants
PlaceboEmesis SeverityAfter ProcedureNone44 Participants
Primary

Nausea Scale

Nausea symptom was collected at different time points via surveys (None, Mild, Moderate, Severe)

Time frame: 1 Day

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
AzithromycinNausea ScaleBaselineNone8 Participants
AzithromycinNausea ScaleBefore ProcedureMild8 Participants
AzithromycinNausea ScaleBefore ProcedureNone34 Participants
AzithromycinNausea ScaleBaselineSevere7 Participants
AzithromycinNausea ScaleAfter ProcedureSevere0 Participants
AzithromycinNausea ScaleAfter ProcedureMild7 Participants
AzithromycinNausea ScaleAfter ProcedureNone35 Participants
AzithromycinNausea ScaleBaselineMild18 Participants
AzithromycinNausea ScaleAfter ProcedureModerate4 Participants
AzithromycinNausea ScaleBefore ProcedureSevere2 Participants
AzithromycinNausea ScaleBefore ProcedureModerate2 Participants
AzithromycinNausea ScaleBaselineModerate13 Participants
DoxycyclineNausea ScaleAfter ProcedureMild5 Participants
DoxycyclineNausea ScaleBaselineNone9 Participants
DoxycyclineNausea ScaleBaselineMild15 Participants
DoxycyclineNausea ScaleBaselineModerate11 Participants
DoxycyclineNausea ScaleBaselineSevere7 Participants
DoxycyclineNausea ScaleBefore ProcedureNone36 Participants
DoxycyclineNausea ScaleBefore ProcedureMild4 Participants
DoxycyclineNausea ScaleBefore ProcedureModerate2 Participants
DoxycyclineNausea ScaleBefore ProcedureSevere0 Participants
DoxycyclineNausea ScaleAfter ProcedureNone28 Participants
DoxycyclineNausea ScaleAfter ProcedureModerate6 Participants
DoxycyclineNausea ScaleAfter ProcedureSevere3 Participants
MetronidazoleNausea ScaleAfter ProcedureModerate1 Participants
MetronidazoleNausea ScaleBefore ProcedureMild5 Participants
MetronidazoleNausea ScaleBefore ProcedureModerate0 Participants
MetronidazoleNausea ScaleBaselineMild10 Participants
MetronidazoleNausea ScaleAfter ProcedureMild6 Participants
MetronidazoleNausea ScaleBefore ProcedureSevere0 Participants
MetronidazoleNausea ScaleAfter ProcedureNone34 Participants
MetronidazoleNausea ScaleBaselineNone6 Participants
MetronidazoleNausea ScaleBaselineSevere5 Participants
MetronidazoleNausea ScaleAfter ProcedureSevere0 Participants
MetronidazoleNausea ScaleBefore ProcedureNone36 Participants
MetronidazoleNausea ScaleBaselineModerate20 Participants
PlaceboNausea ScaleAfter ProcedureSevere0 Participants
PlaceboNausea ScaleBaselineSevere9 Participants
PlaceboNausea ScaleBefore ProcedureMild5 Participants
PlaceboNausea ScaleBaselineMild14 Participants
PlaceboNausea ScaleAfter ProcedureModerate0 Participants
PlaceboNausea ScaleAfter ProcedureNone37 Participants
PlaceboNausea ScaleBefore ProcedureModerate0 Participants
PlaceboNausea ScaleBaselineModerate16 Participants
PlaceboNausea ScaleAfter ProcedureMild8 Participants
PlaceboNausea ScaleBefore ProcedureNone39 Participants
PlaceboNausea ScaleBefore ProcedureSevere1 Participants
PlaceboNausea ScaleBaselineNone6 Participants
Secondary

Endometrial Growth

Endometrial Growth on non-selective, Staph Selective, Strep Selective, and Gram negative selective Agar

Time frame: 3 Days

Population: Subset of patients with endometrial swab cultured

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
AzithromycinEndometrial GrowthStreptococcus Agar (Strep selective)1 Participants
AzithromycinEndometrial GrowthTrypic Soy Non-Selective Agar3 Participants
AzithromycinEndometrial GrowthMacConkey Agar (gram neg selective)0 Participants
AzithromycinEndometrial GrowthMannitol Salt Agar (Staph selective)1 Participants
AzithromycinEndometrial GrowthNo Growth4 Participants
DoxycyclineEndometrial GrowthMannitol Salt Agar (Staph selective)2 Participants
DoxycyclineEndometrial GrowthStreptococcus Agar (Strep selective)1 Participants
DoxycyclineEndometrial GrowthMacConkey Agar (gram neg selective)0 Participants
DoxycyclineEndometrial GrowthTrypic Soy Non-Selective Agar4 Participants
DoxycyclineEndometrial GrowthNo Growth7 Participants
MetronidazoleEndometrial GrowthMannitol Salt Agar (Staph selective)0 Participants
MetronidazoleEndometrial GrowthNo Growth8 Participants
MetronidazoleEndometrial GrowthTrypic Soy Non-Selective Agar3 Participants
MetronidazoleEndometrial GrowthStreptococcus Agar (Strep selective)1 Participants
MetronidazoleEndometrial GrowthMacConkey Agar (gram neg selective)0 Participants
PlaceboEndometrial GrowthStreptococcus Agar (Strep selective)3 Participants
PlaceboEndometrial GrowthTrypic Soy Non-Selective Agar2 Participants
PlaceboEndometrial GrowthNo Growth1 Participants
PlaceboEndometrial GrowthMannitol Salt Agar (Staph selective)1 Participants
PlaceboEndometrial GrowthMacConkey Agar (gram neg selective)0 Participants
Secondary

Pain Scale

Pain symptoms will be collected at different time points via surveys (None, Mild, Moderate, Severe)

Time frame: Day 1

Population: 4 patients had incomplete post-procedure surveys: 1 in Azithromycin group, 2 in Metronidazole group, 1 in Placebo group

ArmMeasureGroupCategoryValue (COUNT_OF_PARTICIPANTS)
AzithromycinPain ScaleAfter ProcedureMild18 Participants
AzithromycinPain ScaleAfter ProcedureSevere3 Participants
AzithromycinPain ScaleBefore ProcedureSevere1 Participants
AzithromycinPain ScaleBaseline PainNone20 Participants
AzithromycinPain ScaleAfter ProcedureNone18 Participants
AzithromycinPain ScaleBaseline PainModerate6 Participants
AzithromycinPain ScaleBaseline PainSevere2 Participants
AzithromycinPain ScaleBaseline PainMild18 Participants
AzithromycinPain ScaleAfter ProcedureModerate6 Participants
AzithromycinPain ScaleBefore ProcedureNone35 Participants
AzithromycinPain ScaleBefore ProcedureMild9 Participants
AzithromycinPain ScaleBefore ProcedureModerate1 Participants
DoxycyclinePain ScaleBaseline PainMild14 Participants
DoxycyclinePain ScaleBefore ProcedureModerate0 Participants
DoxycyclinePain ScaleBaseline PainSevere3 Participants
DoxycyclinePain ScaleAfter ProcedureNone16 Participants
DoxycyclinePain ScaleAfter ProcedureMild17 Participants
DoxycyclinePain ScaleBefore ProcedureSevere0 Participants
DoxycyclinePain ScaleBaseline PainNone17 Participants
DoxycyclinePain ScaleBefore ProcedureMild4 Participants
DoxycyclinePain ScaleBefore ProcedureNone38 Participants
DoxycyclinePain ScaleBaseline PainModerate8 Participants
DoxycyclinePain ScaleAfter ProcedureSevere2 Participants
DoxycyclinePain ScaleAfter ProcedureModerate7 Participants
MetronidazolePain ScaleBefore ProcedureSevere0 Participants
MetronidazolePain ScaleBaseline PainNone16 Participants
MetronidazolePain ScaleBaseline PainMild16 Participants
MetronidazolePain ScaleBaseline PainModerate6 Participants
MetronidazolePain ScaleBaseline PainSevere3 Participants
MetronidazolePain ScaleBefore ProcedureNone35 Participants
MetronidazolePain ScaleBefore ProcedureMild6 Participants
MetronidazolePain ScaleBefore ProcedureModerate0 Participants
MetronidazolePain ScaleAfter ProcedureNone9 Participants
MetronidazolePain ScaleAfter ProcedureMild17 Participants
MetronidazolePain ScaleAfter ProcedureModerate12 Participants
MetronidazolePain ScaleAfter ProcedureSevere1 Participants
PlaceboPain ScaleBefore ProcedureMild5 Participants
PlaceboPain ScaleBefore ProcedureNone39 Participants
PlaceboPain ScaleBaseline PainNone13 Participants
PlaceboPain ScaleAfter ProcedureMild16 Participants
PlaceboPain ScaleBaseline PainSevere3 Participants
PlaceboPain ScaleBaseline PainModerate11 Participants
PlaceboPain ScaleAfter ProcedureSevere2 Participants
PlaceboPain ScaleAfter ProcedureModerate11 Participants
PlaceboPain ScaleBefore ProcedureSevere0 Participants
PlaceboPain ScaleBefore ProcedureModerate1 Participants
PlaceboPain ScaleBaseline PainMild18 Participants
PlaceboPain ScaleAfter ProcedureNone15 Participants
Secondary

Serum Antibiotic Levels

Serum antibiotic levels drawn at time of endometrial sampling in subset of patients

Time frame: 3 hours

Population: Subset of patients who had serum antibiotic levels drawn

ArmMeasureValue (MEAN)Dispersion
AzithromycinSerum Antibiotic Levels0.41 mcg/mLStandard Deviation 0.22
DoxycyclineSerum Antibiotic Levels1.1 mcg/mLStandard Deviation 0.8
MetronidazoleSerum Antibiotic Levels8.2 mcg/mLStandard Deviation 3.8

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026